早期心房动患者的早期节律控制策略
Yiwei Liu1,2, Xiaowei Chen2, Hongbo Lin3
1Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University Health Science Center.
International heart journal
|November 13, 2024
概括
在心房的患者中,早期节律控制 (ERC) 与常规护理 (UC) 相比,显著减少了主要心血管事件 (MACE) 和心力衰竭 (HF). 这一发现支持ERC作为管理早期AF的有益策略.
科学领域:
- 心脏病学 心脏病学
- 临床医学 临床医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在心房动 (AF) 治疗中开始节律控制的最佳时间仍然是争论的主题.
- 最近的证据表明,早期节律控制 (ERC) 可能比常规护理 (UC) 更有利,特别是对于具有较高CHA 2 DS 2 -VASc分数的患者.
研究的目的:
- 调查ERC在早期AF患者中除了降低中风风险之外提供心血管益处的假设,无论他们的CHA 2 DS 2 -VASc分数如何.
- 为了比较ERC和UC策略之间的重大不良心血管事件 (MACE) 在现实世界队列中的发生率.
主要方法:
- 一项回顾性队列研究利用了州地区医疗保健数据库.
- 包括被诊断患有早期AF的患者,但缺少数据,缺乏治疗处方或同时患有癌症的患者除外.
- 应用治疗权重的逆概率 (IPTW) 来调整基线共变量,MACE是主要结果.
主要成果:
- 这项研究包括7,161名早期AF患者 (2,248名ERC,4,913名UC) 进行了平均3.2年的随访.
- 在IPTW之后,ERC表明MACE的风险明显降低 (HR:0.75 [0.61,0.96],P = 0.02) 和心力衰竭 (HF) (HR:0.71 [0.54,0.95],P = 0.01).
- 两组之间在中风,心血管死亡或全因死亡率方面没有发现显著差异.
结论:
- 早期节律控制 (ERC) 与与常规护理 (UC) 相比,与早期心房动患者的心血管结果的改善有关.
- ERC显著降低了主要不良心血管事件 (MACE) 和心力衰竭 (HF) 的风险,突出了其临床实用性.
- 这些发现表明,应强烈考虑ERC用于管理早期AF,以减轻心血管风险.
相关概念视频
Disturbances in Heart Rhythm
908
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
908
Pulse rhythm
768
Pulse rhythm refers to the pattern of pulsations within specific intervals, offering valuable insights into the regularity or irregularity of the heart's beats as observed through the pattern of pulsation within specific intervals. A regular pulse exhibits a consistent heart rate with uniform waveforms and pulsation force, variations of which can be classified as normal, weak, or bounding.
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
768
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
707
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
707
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.2K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
782
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
782
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
911
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
911


